Methods and compositions for impairing multiplication of HIV-1
AssigneeThymon L.L.C.
InventorGideon Goldstein
Life of this patent
Estimating the term…
Abstract
A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain the antibodies induced by the peptide compositions for use in passive therapy. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients
Claims39
A composition comprising a nucleic acid sequence encoding at least two variants of the amino acid sequence R1-Val-Asp-Pro-Y-Leu-Glu-Pro-R2 SEQ ID NO:
- 36, wherein each variant has a different amino acid at Y, said Y being selected from the group consisting of Arg, Lys, Ser and Asn, wherein R1 is a sequence of up to 5 amino acids, wherein R2 is a sequence of up to 14 additional amino acids, or a fragment thereof, wherein said amino acid sequences or fragments induce antibodies that bind to HIV-1 Tat proteins from different HIV-1 strains and subtypes.
The composition according to claim 21, wherein said third amino acid sequence is selected from among the sequences of SEQ ID NOS:
- 27, 40, 50, and 51.
A composition comprising a nucleic acid sequence encoding an amino acid sequence R3-Lys-X-Leu-Gly-Ile-Ser-Tyr-Gly-Arg-Lys-Lys-R4 of SEQ ID NO:
- 37, wherein said amino acid X is either Gly or Ala, wherein R3 is a sequence of between 1 to about 5 additional amino acids;
- and wherein R4 is a sequence of between about 1 to about 5 additional amino acids;
- or a fragment thereof, wherein said amino acid sequence or fragment induces antibodies that bind to HIV-1 Tat proteins from different HIV-1 strains and subtypes.
Dependencies are inferred from the claim text.